Do different bariatric surgery procedures impact hepassocin plasma levels in patients with type 2 diabetes mellitus

ABSTRACT Background and aim Hepassocin is a liver-derived protein and its serum concentrations significantly increase in diabetes and fatty liver patients. Hepassocin can also be a biomarker for diabetes and fatty liver; therefore we aimed to investigate the impacts of different types of bariatric surgery on hepassocin plasma levels in obese patients with diabetes, and to determine if hepassocin could be a potential new marker for monitoring the effects of bariatric surgery and even a treatment target. Methods Overall, 12 patients undergoing gastric bypass (GB), 10 patients undergoing sleeve gastrectomy (SG) and 11 patients undergoing duodeno-jejunal bypass with sleeve gastrectomy (DJB-SG) were enrolled. Fasting hepassocin levels were measured at baseline, 3 months, 12 months and 24 months after surgery. Results The GB, SG and DJB-SG groups significantly decreased their body mass index (BMI), waist-to-hip ratio, a body shape index (ABSI), triglycerides, fasting blood sugar (FBS), hemoglobin A1c, C-peptide levels and homeostasis model assessment of insulin resistance (HOMA-IR) 24 months after surgery. There were no significant changes in hepassocin levels even 24 months after the GB, SG or DJB-SG. However, hepassocin had a significant negative relationship with the ABSI (P Conclusions Neither GB, SG nor DJB-SG altered plasma hepassocin levels in diabetic patients up to 24 months after surgery. Plasma hepassocin concentrations have a negative correlation with the ABSI 24 months after SG.